What Researchers Did
Researchers conducted a randomized controlled trial to evaluate the efficacy of N-Butylphthalide combined with hyperbaric oxygen therapy (HBO) versus HBO alone for cognitive dysfunction in 184 patients with delayed encephalopathy after acute carbon monoxide poisoning (DEACMP).
What They Found
After eight weeks, the experimental group (N-Butylphthalide + HBO) demonstrated a significantly higher total remission rate of 47.9% compared to the control group (HBO alone) at 33.3%. Additionally, significantly more patients in the experimental group achieved MMSE scores of 24-30, indicating improved cognitive function, and showed better neurological function with lower NIHSS scores.
What This Means for Canadian Patients
For Canadian patients experiencing delayed encephalopathy after carbon monoxide poisoning, this study suggests that adding N-Butylphthalide to hyperbaric oxygen therapy could potentially improve cognitive and neurological recovery. This combination therapy might offer a more effective treatment option to enhance remission rates and reduce long-term disability.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
A limitation not explicitly detailed in the abstract could be the relatively short eight-week follow-up period, which may not capture long-term outcomes.